Real-World Comparison of Zanubrutinib Versus Acalabrutinib
August 11, 2026
Real-world data suggests that patients with CLL treated with first-line zanubrutinib have better outcomes than those treated with acalabrutinib.
Real-world data suggests that patients with CLL treated with first-line zanubrutinib have better outcomes than those treated with acalabrutinib.
As anyone who has followed trends in chronic lymphocytic leukemia (CLL) knows, the treatment options for patients with this disease have evolved greatly over the past two decades.
Delaying the addition of obinutuzumab to acalabrutinib-venetoclax to the second yearby one year significantly reduced the risk of infections in patients with CLL.
Limiting acalabrutinib therapy to 18 months significantly reduced progression-free survival for the elderly and frail with CLL compared to continuous use.
The FDA has approved acalabrutinib and venetoclax as the first all oral combination for previously untreated CLL patients based on the AMPLIFY trial data.
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
The EU commission has approved acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the frontline treatment of CLL.
As Inflation Reduction Act negotiations begin, CLL Society is ensuring CMS understands the importance of treatments for CLL patients and physicians.